Mostrar el registro sencillo del ítem

dc.contributor.authorAcosta, Y Y
dc.contributor.authorMontes-Casado, Maria 
dc.contributor.authorAragoneses-Fenoll, Laura 
dc.contributor.authorDianzani, U
dc.contributor.authorPortoles, Pilar 
dc.contributor.authorRojo, J M
dc.date.accessioned2020-06-01T07:57:00Z
dc.date.available2020-06-01T07:57:00Z
dc.date.issued2014-01
dc.identifier.citationInt J Immunopathol Pharmacol. 2014 Jan-Mar;27(1):53-67.es_ES
dc.identifier.issn0394-6320es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/10237
dc.descriptionCorrigendum: Suppression of CD4+ T lymphocyte activation in vitro and experimental encephalomyelitis in vivo by the phosphatidyl inositol 3-kinase inhibitor PIK-75. Int J Immunopathol Pharmacol. 2015 Mar;28(1):146. doi: 10.1177/0394632015572738. PMID: 25816420.
dc.description.abstractClass IA phosphatidyl inositol-3 kinases (PI3-K) are important targets in cancer therapy and are essential to immune responses, particularly through costimulation by CD28 and ICOS. Thus, small PI3-K inhibitors are likely candidates to immune intervention. PIK-75 is an efficient inhibitor of the PI3-K p110alpha catalytic subunits that suppresses tumor growth, and its effects on immune and autoimmune responses should be studied. Here, we describe the effect of PIK-75 on different immune parameters in vitro and in vivo. PIK-75 at concentrations commonly used in vitro (≥0.1 μM) inhibited T and B cell activation by Concanavalin A and LPS, respectively, and survival of non-stimulated spleen cells. In naive CD4+ T lymphocytes, PIK-75 induced apoptosis of resting or activated cells that was prevented by caspase inhibitors. At low nanomolar concentrations (≤10 nM), PIK-75 inhibited naive CD4+ T cell proliferation, and IL-2 and IFN-gamma production induced by anti-CD3 plus anti-CD28. In activated CD4+ T blasts costimulated by ICOS, PIK-75 (less than 10 nM) inhibited IFN-gamma, IL-17A, or IL-21 secretion. Furthermore, PIK-75 (20 mg/kg p.o.) suppressed clinical symptoms in ongoing experimental autoimmune encephalomyelitis (EAE) and inhibited MOG-specific responses in vitro. Thus, PIK-75 is an efficient suppressor of EAE, modulating lymphocyte function and survival.es_ES
dc.description.sponsorshipY.Y.A. is recipient of a Predoctoral Fellowship of the "Junta deAmpliacion de Estudios" (JAE) Program (e.S.I.e., Ministerio de Ciencia e Innovacion, Spain). P.P. is a Tenured Sciencist of e.S.I.e. at the Centro Nacional de Microbiologia, Instituto de Salud Carlos III. This work was supported by Grants PI070620, PI070484 (Plan Estatal I+D+i, ISCIIISubdireccion General de Evaluaci6n y Fomento de la Investigacion, Ministerio de Economia y Competitividad, Spain) to J.M.R. and P.P, and by Associazione Italiana Ricerca sui Cancro (AIRC, Milan) to U.D.es_ES
dc.language.isoenges_ES
dc.publisherSAGE Publishing es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subject.meshAnimalses_ES
dc.subject.meshApoptosises_ES
dc.subject.meshCD4-Positive T-Lymphocyteses_ES
dc.subject.meshCells, Culturedes_ES
dc.subject.meshCytokineses_ES
dc.subject.meshDose-Response Relationship, Druges_ES
dc.subject.meshEncephalomyelitis, Autoimmune, Experimentales_ES
dc.subject.meshFemalees_ES
dc.subject.meshHydrazoneses_ES
dc.subject.meshLymphocyte Activationes_ES
dc.subject.meshMicees_ES
dc.subject.meshMice, Inbred C57BLes_ES
dc.subject.meshSulfonamideses_ES
dc.subject.meshPhosphoinositide-3 Kinase Inhibitorses_ES
dc.titleSuppression of CD4+ T lymphocyte activation in vitro and experimental encephalomyelitis in vivo by the phosphatidyl inositol 3-kinase inhibitor PIK-75es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID24674679es_ES
dc.format.volume27es_ES
dc.format.number1es_ES
dc.format.page53-67es_ES
dc.identifier.doi10.1177/039463201402700108es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) 
dc.contributor.funderMinisterio de Economía y Competitividad (España) 
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.1177/039463201402700108es_ES
dc.identifier.journalInternational journal of immunopathology and pharmacologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI070620,es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI070484es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-CompartirIgual 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-NoComercial-CompartirIgual 4.0 Internacional